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·~ menstrous woman would dull a mirror with a look and the next 
person to look into it would be bewitched. " - Aristotle 
bility that recurrent perimenstrual mood changes of this kind can 
increase the likelihood of chronic mood disorders in susceptible 
individuals. 7 
In 1931 an American gynecologist named Frank1 described 15 
cases of women who had premenstrual symptoms. Thereafter, 
many studies on premenstrual syndrome (PMS) followed but 
most were flawed by serious methodological problems, includ-
ing poor patient selection, no universal definition of the syn-
drome, mainly open uncontrolled studies, and retrospective 
rating of symptoms, which tends to overestimate the prevalence 
Etiology 
A number of etiological theories for PMS have been suggested 
that include biological, psychodynamic, family, social, and 
cognitive components. 8 The current consensus is that normal 
ovarian function is the cyclical trigger for biochemical or 
neurotransmitter events within the central nervous system and 
other target tissues which cause the symptoms. Studies of 
platelet and whole blood serotonin concentration suggest sero-
tonin deficiency in patients with PMS.9 
ofPMS.2 
The third edition of the Diagnostic and Statistical Manual of 
MentalDisordersproposed the termLateLutealPhaseDysphoric 
Disorder (LLPDD), which refers to the mood disturbance of 
premenstrual syndrome and excludes women who have symp-
toms throughout the luteal phase of the cycle. In the latest edition 
of this manual (DSM IV), this condition was not granted an 
official category. Instead, it was renamed Premenstrual Dysphoric 
Disorder (PDD) and relegated to an appendix that contains a 
number of proposals for new categories and axes provided for 
further study. Table 1 summarizes the criteria for PDD. In this 
Evaluation 
It is important to have patients with suspected PMS prospec-
tively rate and record their symptoms and the severity on a daily 
basis. Table 2 lists symptoms that are important to track. Other 
factors to include in the daily diary are basal body temperatures 
(to keep track of ovulation), weight, menstruation, and stress 
factors. Using DSM-IV criteria, the diagnosis is only confirmed 
by the use of prospective ratings during the course of2 menstrual 
cycles. Recording symptoms retrospectively is inaccurate and 
article, PMS is used interchangeably with PDD. 
PMS remains a controversial issue. It is seen by some as a way 
to reduce the status of women, by linking 
the normal ovarian cycle to the impair- ....-------------------------------, 
ment of women's ability to cope.3 Others 
have gone further, labeling psychiatry as 
an institution that exerts social control 
over women by influencing and reflecting 
societal definitions of sex-role-appropri-
ate behavior. By this view, definitions of 
PMS reflect ideology rather than science. 4 
Yet there are a substantial number of 
women who experience significant nega-
tive changes that vary with the menstrual 
cycle. It is estimated that up to 90% of 
women report isolated or minor premen-
strual changes. 5 Around 5% of symptom-
atic women report symptoms severe 
enough to produce long-term effects on 
their well-being and family, social and 
work relationships. Symptoms may be so 
severe that they lead to completed suicide, 
suicide attempts, and acts of violence 
against others.6 There is also a real possi-
Table 1.-DSMIV Research Criteria for Premenstrual Dysphoric 
Disorder 
A. In most menstrual cycles during the past year. 5 or more of the following symptoms were present for most of the 
time during the last week of the luteal phase (the period between ovulation and onset of menses). began to rernh 
within a few days aher the onset of the follicular phase (the period between onset of menses and ovulation), and 
were absent in the week post menses, with at least one of the symptoms being etther 1, 2, 3 or 4. 
1. Markedly depressed mood, feelings of hopelessness, or seK·deprecatlng thoughts. 
2. Marked anxiety, tension, feelings of being "keyed up• or "on edge." 
3. Marked affective labilhy, eg, feeling suddenly sad, tearful; Increased senshlvtty to rejection. 
4. Persistent and marked anger or lrritabilhy or increased Interpersonal conflicts. 
5. Decreased Interest in usual activhies, eg, work, school. friends, hobbles. 
6. Subjective sense of dllflcuhy In concentrating. 
7. Lethargy, easily fatigued or marked lack of energy. 
8. Marked change In appettte, overeating, or specilic food cravings. 
9. Hypersomnia or Insomnia 
10. A subjective sense of being overwhelmed or out of control 
11. Other physical symptoms, such as breast tenderness or swelling, headaches, joint or muscle pain, a 
sensation of bloating, and weight gain. 
B. The disturbance markedly interferes whh work or school orwhh usual social actlvtties and relationships whh others. 
C. The disturbance Is not merely an exacerbation of the symptoms of another disorder, such as Major Depressive 
Disorder, Panic Disorder, Dysthymic Disorder, or a Personalhy Disorder (affhough h may be superimposed on any 
of these cond"ions). 
D. Criteria A, B. and C must be confirmed by prospective daily ratings during at least 2 consecutive symptomatic 
cycles. 
-
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Table 2.-PMS Symptoms for Prospective Charting 
Physical 
Abdominal distention or bloallng 
Mastalgia 
Headache or migraine 
CrarJllll 
Muscle/joint pains 
Psychological 
Angerftrritabllity 
Depressed mood 
Crying 
Suicidal thoughts 
Energy levels 
Food cravings, appetite 
Peeling nervous 
Feeling out of control 
Feelings of violence/aggression 
Poor lnl:lulse control 
should not be used as a basis for treatment.10 The process of 
having a patient keep a daily chart also helps her feel that her 
symptoms are validated and that she participates in the process 
of evaluation and treatment. 
It is important to rule out other medical, gynecologic, and 
psychiatric illnesses; endocrine disorders or premenstrual exac-
erbation of another underlying disorder should be considered. 
Examples include seizure disorders, thyroid disorders, cancer, 
systemic lupus erythematosus, anemias, and various infections. 
These general medical conditions can be distinguished from 
PMS by history, physical examination, and laboratory testing. 
Polycystic ovarian disease and endometriosis also should be 
ruled out. The symptoms of these disorders could present as 
PMS, but the underlying gynecologic disease should be treated 
first. 
It is important to rule out other psychiatric illness such as an 
affective disorder. The transient mood changes that many women 
experience around the time of their period should not be consid-
ered a mental disorder; however, when persistent with every 
cycle and severe enough to markedly interfere with work or 
school or with usual social activities and relationships, address-
ing the mood component becomes crucial. 
Premenstrual exacerbation of a current mental disorder ( eg, 
mood disorders, anxiety disorders) needs to be ruled out. Fifty 
percent to 60% of patients presenting to PMS clinics will meet 
criteria for other psychiatric disorders. 11•12 Treatment of the 
underlying disorder often leads to satisfying results. It also is 
important to screen for histories of physical or sexual abuse and 
substance abuse disorders. A formal psychiatric evaluation may 
help to clarify the diagnosis in difficult cases. 
O'Brien6 described a gonadotrophin-releasing hormone 
(GNRH) analogue test that is useful in diagnosing women who 
have severe symptoms and in whom the diagnosis remains in 
doubt. Goserelin, a GNRH agonist analogue, is given monthly 
for 3 months to eliminate cyclical ovarian function completely. 
Complete elimination of symptoms implies that the symptoms 
are solely dependent on ovarian activity, and the diagnosis is 
PMS. If symptoms continue into the third month, an underlying 
-
psychiatric problem could be present. 
Treatment 
The etiology of PMS is certainly more complex than the 
combination of ovarian activity and neurotransmitter changes. 
Other factors may play a role, including environmental, 
psychosocial, and personal factors. Stress, interpersonal rela-
tionship problems, underlying psychopathology, personality, 
self-esteem, general health and well-being may all be important. 
Therefore, nonspecific measures such as counseling, stress 
management, relaxation techniques, support groups, vitamin 
therapy, dietary change, and exercise can be helpful. (Table 3) 
There is a greater reactivity to stress and a higher level of 
arousal during the premenstruum. 13 A recent study reported 
remission of symptoms in 58% of patients participating in a 
group behavioral treatment, which included instruction on diet, 
exercise, progressive relaxation, and stress reduction, with an-
other quarter of subjects reporting 50% reduction in symp-
toms.14 
Dietary change, vitamin therapy and exercise all improve 
Table 3.-Treatment Approaches for PMS/PDD 
Treatment 
Non-Pharmacological Approaches 
Counseling 
Stress management 
Relaxation techniques 
Support groups 
Exercise 
Dietary and vitamin therapy 
Pharmacological Approaches 
Dosage 
Pyridoxine (86) 100 mg dally 
PfOl!esterone Pessaries/suppositories 400 mg to 800 mg up to twice daily 
Spin no lactone 100 mg daily in 2nd haK of cycle 
Fluoxetine 20 mg daily (or other SRI at equivalent dose) 
Clomipramine 25 mg to 75 mg dally 
Buspirone 10 mg to 30 mg dally in 3 divided doses 
Alprazolam 2 mg to 4 mg daily in 3 to 4 divided doses 
Eliminating the Ovarian Trigger 
Oral contraceptives 
Danazol 100,200,400 mg daily 
GNRH analogues 
Surgery 
3 to 6 mg sc every 28 days for up to 6 months 
total hysterectomy with bilateral salpingo-oophorectomy 
general health and self-esteem and may increase women's 
tolerance to premenstrual symptoms. Meals to combat premen-
strual hypoglycemia have no justification. Vitamin B 6, calcium 
and magnesium may be useful in that they are cofactors in 
neurotransmitter synthesis (eg, conversion of tryptophan to 
serotonin).u Evening primrose oil (efamol), a prostaglandin 
synthesis precursor, may be helpful in relieving breast symp-
toms and depression in some patients.16,I7 
There has been widespread use of progesterone based on 
studies suggesting that estrogen is high relative to progesterone 
in patients suffering from PMS. However, randomized, double-
blind placebo trials have not supported their efficacy.18 
Most women who develop premenstrual bloating and abdomi-
nal distention in the luteal phase do not show increases in weight, 
~ Continued on Page 259 
HAWAII MEDICAL JOURNAL, VOL. 53, SEPTEMBER1994 
255 
Premenstrual Syndrome: A Guide for the Clinician 
>-(Continued from Page 255) 
References 
1. Frank RT. Hormonal causes of premenstrual tension. Arch Neurof Psychiatry. 1931 ;26:1053-57. 
2. Gitlin MJ, Pasnau RO. Psychiatric syndromes linked to reproductive function in women: a review 
of current knowledge. Am J Psychiatty. 1989;146:11. 
total body water, extracellular fluid volume, total exchangeable 3. BancrottJ. The premenstrual syndrome- a reappraisal of the concept and the evidence. Psycho! 
Med Suppl. 1993;24:1-47. 
body sodium, or plasma volume.6 Diuretics are widely used, 4. CaplanPJ,McCurdy-MyersJ,GansM. Should'premenstrualsyndrome"becalledapsychiatric 
however, they might be most helpful in the subgroup of women abnormality? Feminism and Psychology. 1992;2:27-44. 
5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. 
with premenstrual weight gain. American Psychiatric Association, Washington, DC. 1994. 
When dysphoria, irritability, and other psychological symp- 6. O'Brien PMS. Helping women wi1h premenstrual syndrome. BMJ(London). 1993;307:1471-5. 
7. Osolsky HJ, Keppel W, Kuczmierczyk. Evaluation and management of premenstrual syndrome 
toms predominate, a trial of a psychotropic may be helpful. in clinical psychiatric practice. J Clin Psychiatty. 1988;49:494-8. 
Antidepressants that inhibit serotonin ( 5HT) re-uptake, such as 8. Osolsky HJ, Blumenthal s (eds). Premenstrual syndrome: current findings and future directions. 
Washington, DC: APA Press; 1985. 
fluoxetine and clomipramine, have been found to be effective in 9. Rapkin AJ. The roie of serotonin in premenstrual syndrome. Clin ObstetGynecol. 1992;35:629-
double-blind trials. 19-21 Other antidepressants have been tried 36. 
10. Metcalf MG. Livesey JH, Wells JE. Assessment of the significance and severity of premenstrual 
with good results in open trials. Buspirone, a 5-HTlA partial tension.ll.comparisonofmethods.JPsychosomRes.1989;33:281-92. 
agonist, also has been shown to be significantly more effective 11. DeJong R, Rubinow D, Roy-Byme P, et al. Premenstrual mood disorder and psychiatric illness. 
. . b'li c . . fu Am J Psychiatty. 1985;142:1359-61. than a placebo for liTlta 1 ty, tat1gue, pain and social nction- 12. Gonsalves L, Gidweni G. Women's issues. In: Matzen RN, Lang RS (eds). Clinical Preventive 
ing in 34 patients treated with a mean daily dose of25 mg 12 days Medicine. Mosby-Year Book;1993. 
prior to menstruation. 22 Alprazolam, a high potency benzodiaz- 13. Rausch JL. Parry BL Treatment of premenstrual mood symptoms. Psychiatr Clin North Am. 
1993; 16: 829-39. 
epine, given only during the premenstruum also is effective for 14. Pearlstein T, Rivera-Tovar A, FrankE, et al. Nonmedical management of late luteal phase 
d d 1 bal . d 1 dysphoricdisorder.JPsychotherapyPracticeandResearoll.1992;1:49-55. moo symptoms an g o Improvement as compare to P a- 15. Kleijnen J, Riet GT. Knipschild P. VItamin B6 in the treatment of the premenstrual syndrome-a 
cebo.23•24 Longitudinal intermittent treatment studies with this review. BrJObstetGynaeco/. 1990;97:847-52. 
drug are currently in progress. Other psychotropics that have 16. KhooSK,MunroC,BattistuttaD.Eveningprimroseoilandtreatrnentofpremenstrualsyndrome. 
Med J Aust. 1990;153:189-92. 
been tried with less promising results include lithium, 17. Puolakka J, Makarainen L, Viinikka L, et al. Biochemical and clinical effects of treating the 
fenfluramine, naltrexone, and clonidine. premenstrual syndrome with prostaglandin synthesis precursors. J Reprod Med. 1985;30:149-
53. 
For severe symptoms that do not respond to less invasive 18. Moline ML. Pharmacologic strategies for managing premenstrual syndrome. Clin Pharm. 
treatments, the next step would be to eliminate the ovarian 1993;12:181-96. 
19. Stone AB, Pearistein TB, Brown WA. Auoxetine in the treatment of late luteal phase dysphoric 
trigger. This can be done through hormonal treatment or through disorder. J Clin Psychiatty. 1991;52:290-3. 
surgical approaches. 20. Menkes DB, Taghavi E; Mason PA, Howard RC. Fluoxetine in premenstrual syndrome. In! Clin 
Psychopharmacol. 1993;8:95-1 02. Oral contraceptives can suppress ovulation but hormonal 21. Sundblad c. Modigh K. Andersch B, Eriksson E. Clomipramine effectively reduces premenstrual 
cyclicity remains. This probably accounts for the unpredictable irritability and dysphoria: a placebo-controlled trial. Acta Psychiatr Scand. 1992;85:39-47. 
22. Rickels K, Freemen E. Sondheimer S. Buspirone in treatment of premenstrual syndrome. Lancet. 
response to such agents. Furthermore, some patients develop 1989;1:m. 
side effects to oral contraceptives that are similar to symptoms 23. Harrison WM, Endicott J, Nee J. Treatment of premenstrual dysphoria wi1h alprozolem. A 
controlled study. Arch Gen Psychiatty. 1990;47: 270.5. 
of PMS. 25 24. SmHh s. Rinehart JS, Ruddock VE, et al. Treatment of premenstrual syndrome wi1h alprazolam: 
Danazol is a synthetic androgenic derivative of ethisterone · resultsofadouble-blind,placebo-controlled,rendomizedcrossoverclinicaltrial. ObstetGynecol. 
h. h h th l . . . d hi 1987;70:37-43. w IC causes ypo a amtc pttUitary-gona otrop n suppres- 25. Backstrom T. Hansson-Malstrom v. Undhe BA. et al. Oral contraceptives in premenstrual 
sion. When given continuously in doses that suppress ovulation syndrome: a randomized comparison of triphasic and monophasic preparations. Contraception. 
and menstruation, the symptoms of PMS are abolished. 26'27 Its 26. ~::;~~:ohjansky N, Palter s. Elimination of ovulation and menstrual cyclicity Improves 
usefulness is limited because of its androgenic properties in dysphoric premenstrual syndrome. Fettil Steril. 1991;56:1066. 
women of childbearing age. 27. DerzkoCM. Rolaofdenazolinrelievingpremenstrualsyndrome.JReprodMed.1990;35(suppl):97-
102. 
GNRH agonist analogues act by creating a reversible 28. MuseK.Hormonalmenipulationinthetreatmentofpramenstrualsyndrome.C/inObsletGyneco/. 
pseudohypophysectomy and, therefore, a pseudomenopause. 29. =~~PM. van Vugt DA. Reid RL. Lasting response to ovariectomy in severe 
Depot goserelin, for instance, has been shown to eradicate intractablepremenstrualsyndrome.AmJObstetGyneco/.1990;162:99-105. 
premenstrual symptoms. 28 Long-term treatment, however, is not 
feasible because of risks of osteoporosis and atherosclerotic 
heart disease. Studies are being conducted in combination with 
adjuvant conventional hormone replacement therapy. 
Surgery may be a last resort for severely affected patients 
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Although the etiology of PMS remains unclear there are 
strategies a clinician can utilize to alleviate symptoms. The 
problem is an important one and deserves our continued clinical 
attention and study. 
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